Sangamo BioSciences Company Profile (NASDAQ:SGMO)

About Sangamo BioSciences

Sangamo BioSciences logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has developed technologies available for gene-based therapies. Its product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Its zinc finger nuclease (ZFN) in vivo genome editing approach is being evaluated in Phase I/II clinical trials to treat hemophilia B and lysosomal storage disorders mucopolysaccharidosis (MPS) I and MPS II. It is also conducting a Phase I/II clinical trial to evaluate its adeno associated virus (AAV) complementary deoxyribonucleic acid (cDNA) human Factor 8 gene therapy approach, SB-525, to treat hemophilia A. It has investigational new drug application for SB-525. It is also developing ZFN-mediated genome editing-based therapies for blood disorders and cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGMO
  • CUSIP: 80067710
Key Metrics:
  • Previous Close: $4.55
  • 50 Day Moving Average: $3.84
  • 200 Day Moving Average: $3.91
  • 52-Week Range: $2.65 - $7.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.46
  • P/E Growth: 0.00
  • Market Cap: $321.33M
  • Outstanding Shares: 70,623,000
  • Beta: 3.22
  • Net Margins: -388.23%
  • Return on Equity: -45.02%
  • Return on Assets: -40.02%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 10.74%
  • Quick Ratio: 10.74%
Additional Links:
Companies Related to Sangamo BioSciences:

Analyst Ratings

Consensus Ratings for Sangamo BioSciences (NASDAQ:SGMO) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $7.75 (70.33% upside)

Analysts' Ratings History for Sangamo BioSciences (NASDAQ:SGMO)
DateFirmActionRatingPrice TargetDetails
3/1/2017WedbushReiterated RatingNeutral$4.00View Rating Details
2/28/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$5.00View Rating Details
8/5/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy -> Neutral$15.00 -> $8.00View Rating Details
5/3/2016Wells Fargo & CoInitiated CoverageBuyView Rating Details
2/10/2016J P Morgan Chase & CoReiterated RatingOverweight$16.00View Rating Details
5/19/2015BMO Capital MarketsReiterated RatingOutperform$19.00View Rating Details
(Data available from 3/1/2015 forward)


Earnings History for Sangamo BioSciences (NASDAQ:SGMO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewN/AView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sangamo BioSciences (NASDAQ:SGMO)
Current Year EPS Consensus Estimate: $-1.14 EPS
Next Year EPS Consensus Estimate: $-1.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.25)($0.25)($0.25)
Q3 20161($0.23)($0.23)($0.23)
Q4 20162($0.27)($0.25)($0.26)
Q1 20172($0.25)($0.25)($0.25)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)


Dividend History for Sangamo BioSciences (NASDAQ:SGMO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sangamo BioSciences (NASDAQ:SGMO)
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 61.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.00View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.00View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.31View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.00View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.00View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.00View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.00View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.00View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sangamo BioSciences (NASDAQ:SGMO)
DateHeadline logoSangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II (NASDAQ:SGMO) - March 1 at 9:59 AM logoSangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results (NASDAQ:SGMO) - February 28 at 12:01 PM logoSANGAMO THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or P (NASDAQ:SGMO) - February 28 at 12:01 PM logo7:07 am Sangamo BioSci beats by $0.11, beats on revs; guides FY17 (NASDAQ:SGMO) - February 28 at 12:01 PM logoQ4 2016 Sangamo Therapeutics Inc Earnings Release - Before Market Open (NASDAQ:SGMO) - February 28 at 12:01 PM logoSangamo reports 4Q loss (NASDAQ:SGMO) - February 28 at 12:01 PM logoSangamo Therapeutics : Announces Chief Financial Officer Succession (NASDAQ:SGMO) - February 27 at 4:35 PM logo8:02 am Sangamo BioSci announces that the FDA has granted rare pediatric disease designation for SB-318 for the treatment of Mucopolysaccharidosis Type I (NASDAQ:SGMO) - February 27 at 4:35 PM logoSangamo Therapeutics Announces Chief Financial Officer Succession (NASDAQ:SGMO) - February 27 at 4:35 PM logoSangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I (NASDAQ:SGMO) - February 27 at 9:18 AM logoBiotech Premarket Movers: BioCryst, Sangamo, Cempra (NASDAQ:SGMO) - February 27 at 9:18 AM logoSANGAMO THERAPEUTICS, INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:SGMO) - February 24 at 9:51 PM logoSANGAMO THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:SGMO) - February 24 at 9:51 PM logoSangamo Therapeutics : Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast (NASDAQ:SGMO) - February 21 at 5:05 PM logoSangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast (NASDAQ:SGMO) - February 21 at 5:05 PM
News IconStock Perspective: Sangamo BioSciences, Inc. (NASDAQ:SGMO) Company Earnings Watch - Aiken Advocate (NASDAQ:SGMO) - February 20 at 6:58 PM
News IconQuarterly EPS Of Sangamo BioSciences, Inc. (NASDAQ:SGMO) Set ... - Stock Observer (NASDAQ:SGMO) - February 11 at 7:51 PM logoSangamo Therapeutics Announces Upcoming Presentations At The 13th Annual WORLDSymposium™ Meeting (NASDAQ:SGMO) - February 9 at 3:21 AM
News IconQuarterly EPS Of Sangamo BioSciences, Inc. (NASDAQ:SGMO) Set At $-0.33 - Stock Observer (NASDAQ:SGMO) - February 5 at 8:05 AM
News IconTicker Tracker: Looking at Sangamo Biosciences Inc. (SGMO) - Rives Journal (NASDAQ:SGMO) - January 29 at 8:04 AM
News IconStock Spotter: Review on Technical Levels for Sangamo Biosciences Inc. (SGMO) - Sherwood Daily (NASDAQ:SGMO) - January 27 at 3:14 AM
News IconWhat is the Sell-side Saying About Sangamo BioSciences, Inc. (NASDAQ:SGMO)? - Aiken Advocate (NASDAQ:SGMO) - January 24 at 1:09 AM logoETFs with exposure to Sangamo Therapeutics, Inc. : January 20, 2017 (NASDAQ:SGMO) - January 21 at 12:56 AM
News IconTraders Attention Alert: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Sangamo BioSciences, Inc (NASDAQ:SGMO) - January 18 at 10:00 PM logoSANGAMO THERAPEUTICS, INC Financials (NASDAQ:SGMO) - January 18 at 10:00 PM
News IconWill The Needle Move For Sangamo BioSciences, Inc. (NASDAQ:SGMO) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:SGMO) - January 17 at 12:30 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Sangamo BioSciences, Inc. (NASDAQ:SGMO) - Wall Street Beacon (NASDAQ:SGMO) - January 15 at 8:14 AM logoSangamo Biosciences (SGMO) Granted FDA Orphan Drug Designation for SB-318 Genome Editing Treatment (NASDAQ:SGMO) - January 12 at 9:45 PM logoSANGAMO THERAPEUTICS INC Financials (NASDAQ:SGMO) - January 12 at 9:45 PM logoSangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I (NASDAQ:SGMO) - January 12 at 4:03 AM logoSangamo Biosciences (SGMO) Granted FDA Orphan Drug ... - (NASDAQ:SGMO) - January 11 at 11:01 PM
News IconStock Reaching Most Volatile List Today: Sangamo BioSciences, Inc. (NASDAQ:SGMO) - Wall Street Beacon (NASDAQ:SGMO) - January 11 at 11:01 PM
News IconSangamo BioSciences, Inc. (NASDAQ:SGMO) Bearish Target At $14 - Stock Observer (NASDAQ:SGMO) - January 11 at 11:01 PM
News IconSangamo BioSciences, Inc. (NASDAQ:SGMO) Daily Sentiment Score At 0.435 - Stock Observer (NASDAQ:SGMO) - January 11 at 3:39 AM logoSangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering (NASDAQ:SGMO) - January 10 at 10:38 PM
News IconSangamo BioSciences Inc SGMO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SGMO) - January 8 at 12:53 AM logoBRIEF-Sangamo Biosciences changes name to Sangamo Therapeutics (NASDAQ:SGMO) - January 8 at 12:53 AM logoAnalyst Activity – Wedbush Reiterates Neutral on Sangamo BioSciences (NASDAQ:SGMO) - Market Exclusive (NASDAQ:SGMO) - January 7 at 3:37 AM logoSangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies (NASDAQ:SGMO) - January 6 at 10:28 PM logoSANGAMO BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia (NASDAQ:SGMO) - January 6 at 10:28 PM logoSangamo Biosciences (SGMO) Reports FDA Clearance of IND for SB-525 Gene Therapy Program For Hemophilia A (NASDAQ:SGMO) - January 6 at 4:01 AM logoAnalyst Activity – Wedbush Reiterates Neutral on Sangamo BioSciences (NASDAQ:SGMO) (NASDAQ:SGMO) - January 6 at 4:01 AM logoSangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A (NASDAQ:SGMO) - January 6 at 4:01 AM logoSangamo BioSciences Announces Presentation At The 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:SGMO) - January 5 at 6:33 AM
News IconDaily Sentiment Score Of Sangamo BioSciences, Inc. (NASDAQ:SGMO) At 0.533 - Stock Observer (NASDAQ:SGMO) - January 3 at 9:43 AM
News IconAre There Catalysts to Propel This Stock Forward: Sangamo BioSciences, Inc. (NASDAQ:SGMO) - Prospect Journal (NASDAQ:SGMO) - January 3 at 9:43 AM logoBiotech Stocks on Investors' Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx (NASDAQ:SGMO) - December 28 at 9:20 AM logoETFs with exposure to Sangamo BioSciences, Inc. : December 21, 2016 (NASDAQ:SGMO) - December 21 at 11:03 PM logoSangamo BioSciences : Assigned Patent (NASDAQ:SGMO) - December 21 at 10:43 AM
News IconChecking the Levels for Sangamo BioSciences, Inc. (NASDAQ:SGMO) - Liberty News (NASDAQ:SGMO) - December 20 at 8:32 PM


What is Sangamo BioSciences' stock symbol?

Sangamo BioSciences trades on the NASDAQ under the ticker symbol "SGMO."

Where is Sangamo BioSciences' stock going? Where will Sangamo BioSciences' stock price be in 2017?

6 brokers have issued 1-year price objectives for Sangamo BioSciences' shares. Their forecasts range from $4.00 to $14.00. On average, they expect Sangamo BioSciences' share price to reach $7.75 in the next twelve months.

When will Sangamo BioSciences announce their earnings?

Sangamo BioSciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Sangamo BioSciences stock?

Here are some recent quotes from research analysts about Sangamo BioSciences stock:

  • Cowen and Company analysts commented, "Today SGMO reported 4Q16." (2/28/2017)

  • Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)
  • According to Zacks Investment Research, "Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins. " (12/31/2016)

Who owns Sangamo BioSciences stock?

Sangamo BioSciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (2.41%), State Street Corp (1.68%), Deerfield Management Co. (1.19%), Royce & Associates LP (1.06%), Orbimed Advisors LLC (1.00%) and Frontier Capital Management Co. LLC (0.72%). Company insiders that own Sangamo BioSciences stock include Dale G Ando, Edward O Lanphier II, Henry Ward Wolff, Philip D Gregory, Ra Capital Management, Llc and William R Ringo.

Who sold Sangamo BioSciences stock? Who is selling Sangamo BioSciences stock?

Sangamo BioSciences' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Orbimed Advisors LLC and Frontier Capital Management Co. LLC.

Who bought Sangamo BioSciences stock? Who is buying Sangamo BioSciences stock?

Sangamo BioSciences' stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Co., Opaleye Management Inc., Royce & Associates LP, Sicart Associates LLC, Tudor Investment Corp Et Al, Russell Investments Group Ltd., A.R.T. Advisors LLC and Keybank National Association OH.

How do I buy Sangamo BioSciences stock?

Shares of Sangamo BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sangamo BioSciences stock cost?

One share of Sangamo BioSciences stock can currently be purchased for approximately $4.55.

Sangamo BioSciences (NASDAQ:SGMO) Chart for Wednesday, March, 1, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Sangamo BioSciences (NASDAQ:SGMO)

Earnings History Chart

Earnings by Quarter for Sangamo BioSciences (NASDAQ:SGMO)

Dividend History Chart

Dividend Payments by Quarter for Sangamo BioSciences (NASDAQ:SGMO)

Last Updated on 3/1/2017 by Staff